|
1
|
Mook OR, Frederiks WM and van Noorden CJ:
The role of gelatinases in colorectal cancer progression and
metastasis. Biochim Biophys Acta. 1705:69–89. 2004.PubMed/NCBI
|
|
2
|
López-Otín C and Matrisian LM: Emerging
roles of proteases in tumour suppression. Nat Rev Cancer.
7:800–808. 2007.PubMed/NCBI
|
|
3
|
Déry O, Corvera CU, Steinhoff M and
Bunnett NW: Proteinase-activated receptors: novel mechanisms of
signaling by serine proteases. Am J Physiol. 274:C1429–C1452.
1998.PubMed/NCBI
|
|
4
|
Macfarlane SR, Seatter MJ, Kanke T, Hunter
GD and Plevin R: Proteinase-activated receptors. Pharmacol Rev.
53:245–282. 2001.PubMed/NCBI
|
|
5
|
Coughlin SR: Thrombin signalling and
protease-activated receptors. Nature. 407:258–264. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Coughlin SR: How the protease thrombin
talks to cells. Proc Natl Acad Sci USA. 96:11023–11027. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hollenberg MD and Compton SJ:
International Union of Pharmacology. XXVIII Proteinase-activated
receptors. Pharmacol Rev. 54:203–217. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ossovskaya VS and Bunnett NW:
Protease-activated receptors: contribution to physiology and
disease. Physiol Rev. 84:579–621. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vu TK, Hung DT, Wheaton VI and Coughlin
SR: Molecular cloning of a functional thrombin receptor reveals a
novel proteolytic mechanism of receptor activation. Cell.
64:1057–1068. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ishihara H, Connolly AJ, Zeng D, Kahn ML,
Zheng YW, Timmons C, Tram T and Coughlin SR: Protease-activated
receptor 3 is a second thrombin receptor in humans. Nature.
386:502–506. 1997. View
Article : Google Scholar : PubMed/NCBI
|
|
11
|
Xu WF, Andersen H, Whitmore TE, Presnell
SR, Yee DP, Ching A, Gilbert T, Davie EW and Foster DC: Cloning and
characterization of human protease-activated receptor 4. Proc Natl
Acad Sci USA. 95:6642–6646. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Coughlin SR and Camerer E: PARticipation
in inflammation. J Clin Invest. 111:25–27. 2003. View Article : Google Scholar
|
|
13
|
Kondo K and Kaelin WG Jr: The von
Hippel-Lindau tumor suppressor gene. Exp Cell Res. 264:117–125.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ohh M, Yauch RL, Lonergan KM, Whaley JM,
Stemmer-Rachamimov AO, Louis DN, Gavin BJ, Kley N, Kaelin WG Jr and
Iliopoulos O: The von Hippel-Lindau tumor suppressor protein is
required for proper assembly of an extracellular fibronectin
matrix. Mol Cell. 1:959–968. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zacharski LR, Memoli VA, Morain WD,
Schlaeppi JM and Rousseau SM: Cellular localization of
enzymatically active thrombin in intact human tissues by hirudin
binding. Thromb Haemost. 73:793–797. 1995.
|
|
16
|
Rickles FR, Patierno S and Fernandez PM:
Tissue factor, thrombin, and cancer. Chest. 124:S58–S68. 2003.
View Article : Google Scholar
|
|
17
|
Maragoudakis ME, Tsopanoglou NE and
Andriopoulou P: Mechanism of thrombin-induced angiogenesis. Biochem
Soc Trans. 30:173–177. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tsopanoglou NE, Pipili-Synetos E and
Maragoudakis ME: Thrombin promotes angiogenesis by a mechanism
independent of fibrin formation. Am J Physiol. 264:C1302–C1307.
1993.PubMed/NCBI
|
|
19
|
Haralabopoulos GC, Grant DS, Kleinman HK
and Maragoudakis ME: Thrombin promotes endothelial cell alignment
in Matrigel in vitro and angiogenesis in vivo. Am J Physiol.
273:C239–C245. 1997.PubMed/NCBI
|
|
20
|
Fujiwara M, Jin E, Ghazizadeh M and
Kawanami O: Activation of PAR4 induces a distinct actin fiber
formation via p38 MAPK in human lung endothelial cells. J Histochem
Cytochem. 53:1121–1129. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Vliagoftis H: Thrombin induces mast cell
adhesion to fibronectin: evidence for involvement of
protease-activated receptor-1. J Immunol. 169:4551–4558. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Kataoka H, Hamilton JR, McKemy DD, Camerer
E, Zheng YW, Cheng A, Griffin C and Coughlin SR: Protease-activated
receptors 1 and 4 mediate thrombin signaling in endothelial cells.
Blood. 102:3224–3231. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Dimitropoulou C, Malkusch W, Fait E,
Maragoudakis ME and Konerding MA: The vascular architecture of the
chick chorioallantoic membrane: sequential quantitative evaluation
using corrosion casting. Angiogenesis. 2:255–263. 1998. View Article : Google Scholar
|
|
24
|
Tsopanoglou NE and Maragoudakis ME: On the
mechanism of thrombin-induced angiogenesis: inhibition of
attachment of endothelial cells on basement membrane components.
Angiogenesis. 1:192–200. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Maragoudakis ME, Kraniti N, Giannopoulou
E, Alexopoulos K and Matsoukas J: Modulation of angiogenesis and
progelatinase a by thrombin receptor mimetics and antagonists.
Endothelium. 8:195–205. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Brooks PC, Strömblad S, Sanders LC, von
Schalscha TL, Aimes RT, Stetler-Stevenson WG, Quigley JP and
Cheresh DA: Localization of matrix metalloproteinase MMP-2 to the
surface of invasive cells by interaction with integrin alpha v beta
3. Cell. 85:683–693. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tsopanoglou NE and Maragoudakis ME: On the
mechanism of thrombin-induced angiogenesis. Potentiation of
vascular endothelial growth factor activity on endothelial cells by
up-regulation of its receptors. J Biol Chem. 274:23969–23976. 1999.
View Article : Google Scholar
|
|
28
|
Liu Y and Mueller BM: Protease-activated
receptor-2 regulates vascular endothelial growth factor expression
in MDA-MB-231 cells via MAPK pathways. Biochem Biophys Res Commun.
344:1263–1270. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Marutsuka K, Hatakeyama K, Sato Y,
Yamashita A, Sumiyoshi A and Asada Y: Protease-activated receptor 2
(PAR2) mediates vascular smooth muscle cell migration induced by
tissue factor/factor VIIa complex. Thromb Res. 107:271–276. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Oikonomopoulou K, Hansen KK, Saifeddine M,
Vergnolle N, Tea I, Diamandis EP and Hollenberg MD:
Proteinase-mediated cell signalling: targeting proteinase-activated
receptors (PARs) by kallikreins and more. Biol Chem. 387:677–685.
2006.PubMed/NCBI
|
|
31
|
Brooks PC, Clark RA and Cheresh DA:
Requirement of vascular integrin alpha v beta 3 for angiogenesis.
Science. 264:569–571. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nelken NA, Soifer SJ, O'Keefe J, Vu TK,
Charo IF and Coughlin SR: Thrombin receptor expression in normal
and atherosclerotic human arteries. J Clin Invest. 90:1614–1621.
1992. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mirza H, Yatsula V and Bahou WF: The
proteinase activated receptor-2 (PAR-2) mediates mitogenic
responses in human vascular endothelial cells. J Clin Invest.
97:1705–1714. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Schmidt VA, Nierman WC, Maglott DR, Cupit
LD, Moskowitz KA, Wainer JA and Bahou WF: The human
proteinase-activated receptor-3 (PAR-3) gene. Identification within
a Par gene cluster and characterization in vascular endothelial
cells and platelets. J Biol Chem. 273:15061–15068. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Camerer E, Huang W and Coughlin SR: Tissue
factor- and factor X-dependent activation of protease-activated
receptor 2 by factor VIIa. Proc Natl Acad Sci USA. 97:5255–5260.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Riewald M and Ruf W: Mechanistic coupling
of protease signaling and initiation of coagulation by tissue
factor. Proc Natl Acad Sci USA. 98:7742–7747. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Camerer E, Kataoka H, Kahn M, Lease K and
Coughlin SR: Genetic evidence that protease-activated receptors
mediate factor Xa signaling in endothelial cells. J Biol Chem.
277:16081–16087. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Garcia JG, Davis HW and Patterson CE:
Regulation of endothelial cell gap formation and barrier
dysfunction: role of myosin light chain phosphorylation. J Cell
Physiol. 163:510–522. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Vouret-Craviari V, Bourcier C, Boulter E
and van Obberghen-Schilling E: Distinct signals via Rho GTPases and
Src drive shape changes by thrombin and sphingosine-1-phosphate in
endothelial cells. J Cell Sci. 115:2475–2484. 2002.PubMed/NCBI
|
|
40
|
Minami T, Sugiyama A, Wu SQ, Abid R,
Kodama T and Aird WC: Thrombin and phenotypic modulation of the
endothelium. Arterioscler Thromb Vasc Biol. 24:41–53. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Carmeliet P: Angiogenesis in life, disease
and medicine. Nature. 438:932–936. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Pinedo HM, Verheul HM, D'Amato RJ and
Folkman J: Involvement of platelets in tumour angiogenesis? Lancet.
352:1775–1777. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Kakkar AK, Levine MN, Kadziola Z, Lemoine
NR, Low V, Patel HK, Rustin G, Thomas M, Quigley M and Williamson
RC: Low molecular weight heparin, therapy with dalteparin, and
survival in advanced cancer: the fragmin advanced malignancy
outcome study (FAMOUS). J Clin Oncol. 22:1944–1948. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Klerk CP, Smorenburg SM, Otten HM, Lensing
AW, Prins MH, Piovella F, Prandoni P, Bos MM, Richel DJ, van
Tienhoven G and Büller HR: The effect of low molecular weight
heparin on survival in patients with advanced malignancy. J Clin
Oncol. 23:2130–2135. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Browder T, Folkman J and Pirie-Shepherd S:
The hemostatic system as a regulator of angiogenesis. J Biol Chem.
275:1521–1524. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Folkman J, Browder T and Palmblad J:
Angiogenesis research: guidelines for translation to clinical
application. Thromb Haemost. 86:23–33. 2001.PubMed/NCBI
|
|
47
|
Kisucka J, Butterfield CE, Duda DG,
Eichenberger SC, Saffaripour S, Ware J, Ruggeri ZM, Jain RK,
Folkman J and Wagner DD: Platelets and platelet adhesion support
angiogenesis while preventing excessive hemorrhage. Proc Natl Acad
Sci USA. 103:855–860. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Ma L, Perini R, McKnight W, Dicay M, Klein
A, Hollenberg MD and Wallace JL: Proteinase-activated receptors 1
and 4 counter-regulate endostatin and VEGF release from human
platelets. Proc Natl Acad Sci USA. 102:216–220. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Pipili-Synetos E, Papadimitriou E and
Maragoudakis ME: Evidence that platelets promote tube formation by
endothelial cells on matrigel. Br J Pharmacol. 125:1252–1257. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Italiano JE Jr, Richardson JL, Patel-Hett
S, Battinelli E, Zaslavsky A, Short S, Ryeom S, Folkman J and
Klement GL: Angiogenesis is regulated by a novel mechanism: pro-
and anti-angiogenic proteins are organized into separate platelet
alpha granules and differentially released. Blood. 111:1227–1233.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Möhle R, Green D, Moore MA, Nachman RL and
Rafii S: Constitutive production and thrombin-induced release of
vascular endothelial growth factor by human megakaryocytes and
platelets. Proc Natl Acad Sci USA. 94:663–668. 1997.PubMed/NCBI
|
|
52
|
Wartiovaara U, Salven P, Mikkola H,
Lassila R, Kaukonen J, Joukov V, Orpana A, Ristimäki A, Heikinheimo
M, Joensuu H, Alitalo K and Palotie A: Peripheral blood platelets
express VEGF-C and VEGF which are released during platelet
activation. Thromb Haemost. 80:171–175. 1998.PubMed/NCBI
|
|
53
|
Kaplan DR, Chao FC, Stiles CD, Antoniades
HN and Scher CD: Platelet alpha granules contain a growth factor
for fibroblasts. Blood. 53:1043–1052. 1979.PubMed/NCBI
|
|
54
|
Ben-Ezra J, Sheibani K, Hwang DL and
Lev-Ran A: Megakaryocyte synthesis is the source of epidermal
growth factor in human platelets. Am J Pathol. 137:755–759.
1990.PubMed/NCBI
|
|
55
|
Nakamura T, Tomita Y, Hirai R, Yamaoka K,
Kaji K and Ichihara A: Inhibitory effect of transforming growth
factor-beta on DNA synthesis of adult rat hepatocytes in primary
culture. Biochem Biophys Res Commun. 133:1042–1050. 1985.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Hla T: Physiological and pathological
actions of sphingosine 1-phosphate. Semin Cell Dev Biol.
15:513–520. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Galt SW, Lindemann S, Allen L, Medd DJ,
Falk JM, McIntyre TM, Prescott SM, Kraiss LW, Zimmerman GA and
Weyrich AS: Outside-in signals delivered by matrix
metalloproteinase-1 regulate platelet function. Circ Res.
90:1093–1099. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Daly ME, Makris A, Reed M and Lewis CE:
Hemostatic regulators of tumor angiogenesis: a source of
anti-angiogenic agents for cancer treatment? J Natl Cancer Inst.
95:1660–1673. 2003.PubMed/NCBI
|
|
59
|
Iruela-Arispe ML, Bornstein P and Sage H:
Thrombospondin exerts an anti-angiogenic effect on cord formation
by endothelial cells in vitro. Proc Natl Acad Sci USA.
88:5026–5030. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Maione TE, Gray GS, Petro J, Hunt AJ,
Donner AL, Bauer SI, Carson HF and Sharpe RJ: Inhibition of
angiogenesis by recombinant human platelet factor-4 and related
peptides. Science. 247:77–79. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Covic L, Gresser AL and Kuliopulos A:
Biphasic kinetics of activation and signaling for PAR1 and PAR4
thrombin receptors in platelets. Biochemistry. 39:5458–5467. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Jamieson GA: Pathophysiology of platelet
thrombin receptors. Thromb Haemost. 78:242–246. 1997.PubMed/NCBI
|
|
63
|
Cottrell GS, Coelho AM and Bunnett NW:
Protease-activated receptors: the role of cell-surface proteolysis
in signalling. Essays Biochem. 38:169–183. 2002.PubMed/NCBI
|
|
64
|
Kahn ML, Zheng YW, Huang W, Bigornia V,
Zeng D, Moff S, Farese RV Jr, Tam C and Coughlin SR: A dual
thrombin receptor system for platelet activation. Nature.
394:690–694. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
65
|
Coughlin SR: Protease-activated receptors
in hemostasis, thrombosis and vascular biology. J Thromb Haemost.
3:1800–1814. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Brass LF: Thrombin and platelet
activation. Chest. 124:S18–S25. 2003. View Article : Google Scholar
|
|
67
|
Vandendries ER, Hamilton JR, Coughlin SR,
Furie B and Furie BC: Par4 is required for platelet thrombus
propagation but not fibrin generation in a mouse model of
thrombosis. Proc Natl Acad Sci USA. 104:288–292. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Holinstat M, Voss B, Bilodeau ML and Hamm
HE: Protease-activated receptors differentially regulate human
platelet activation through a phosphatidic acid-dependent pathway.
Mol Pharmacol. 71:686–694. 2007. View Article : Google Scholar
|
|
69
|
Holinstat M, Voss B, Bilodeau ML,
McLaughlin JN, Cleator J and Hamm HE: PAR4, but not PAR1, signals
human platelet aggregation via Ca2+ mobilization and
synergistic P2Y12 receptor activation. J Biol Chem.
281:26665–26674. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Kahn ML, Nakanishi-Matsui M, Shapiro MJ,
Ishihara H and Coughlin SR: Protease-activated receptors 1 and 4
mediate activation of human platelets by thrombin. J Clin Invest.
103:879–887. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Andersen H, Greenberg DL, Fujikawa K, Xu
W, Chung DW and Davie EW: Protease-activated receptor 1 is the
primary mediator of thrombin-stimulated platelet procoagulant
activity. Proc Natl Acad Sci USA. 96:11189–11193. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Wu CC, Wu SY, Liao CY, Teng CM, Wu YC and
Kuo SC: The roles and mechanisms of PAR4 and
P2Y12/phosphatidylinositol 3-kinase pathway in maintaining
thrombin-induced platelet aggregation. Br J Pharmacol. 161:643–658.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Shapiro MJ, Weiss EJ, Faruqi TR and
Coughlin SR: Protease-activated receptors 1 and 4 are shut off with
distinct kinetics after activation by thrombin. J Biol Chem.
275:25216–25221. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Nierodzik ML, Plotkin A, Kajumo F and
Karpatkin S: Thrombin stimulates tumor-platelet adhesion in vitro
and metastasis in vivo. J Clin Invest. 87:229–236. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Nierodzik ML, Kajumo F and Karpatkin S:
Effect of thrombin treatment of tumor cells on adhesion of tumor
cells to platelets in vitro and tumor metastasis in vivo. Cancer
Res. 52:3267–3272. 1992.PubMed/NCBI
|
|
76
|
Darmoul D, Gratio V, Devaud H, Lehy T and
Laburthe M: Aberrant expression and activation of the thrombin
receptor protease-activated receptor-1 induces cell proliferation
and motility in human colon cancer cells. Am J Pathol.
162:1503–1513. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Darmoul D, Gratio V, Devaud H, Peiretti F
and Laburthe M: Activation of proteinase-activated receptor 1
promotes human colon cancer cell proliferation through epidermal
growth factor receptor transactivation. Mol Cancer Res. 2:514–522.
2004.
|
|
78
|
Chiang HS, Yang RS and Huang TF: Thrombin
enhances the adhesion and migration of human colon adenocarcinoma
cells via increased beta 3-integrin expression on the tumour cell
surface and their inhibition by the snake venom peptide,
rhodostomin. Br J Cancer. 73:902–908. 1996. View Article : Google Scholar
|
|
79
|
Chen HT, Tsou HK, Tsai CH, Kuo CC, Chiang
YK, Chang CH, Fong YC and Tang CH: Thrombin enhanced migration and
MMPs expression of human chondrosarcoma cells involves PAR receptor
signaling pathway. J Cell Physiol. 223:737–745. 2010.PubMed/NCBI
|
|
80
|
Kaufmann R, Rahn S, Pollrich K, Hertel J,
Dittmar Y, Hommann M, Henklein P, Biskup C, Westermann M,
Hollenberg MD and Settmacher U: Thrombin-mediated hepatocellular
carcinoma cell migration: cooperative action via
proteinase-activated receptors 1 and 4. J Cell Physiol.
211:699–707. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Miyata S, Koshikawa N, Yasumitsu H and
Miyazaki K: Trypsin stimulates integrin alpha(5)beta(1)-dependent
adhesion to fibronectin and proliferation of human gastric
carcinoma cells through activation of proteinase-activated
receptor-2. J Biol Chem. 275:4592–4598. 2000. View Article : Google Scholar
|
|
82
|
Even-Ram S, Uziely B, Cohen P,
Grisaru-Granovsky S, Maoz M, Ginzburg Y, Reich R, Vlodavsky I and
Bar-Shavit R: Thrombin receptor overexpression in malignant and
physiological invasion processes. Nat Med. 4:909–914. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Wojtukiewicz MZ, Tang DG, Nelson KK, Walz
DA, Diglio CA and Honn KV: Thrombin enhances tumor cell adhesive
and metastatic properties via increased alpha IIb beta 3 expression
on the cell surface. Thromb Res. 68:233–245. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Wojtukiewicz MZ, Tang DG, Ciarelli JJ,
Nelson KK, Walz DA, Diglio CA, Mammen EF and Honn KV: Thrombin
increases the metastatic potential of tumor cells. Int J Cancer.
54:793–806. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Hughes PE and Pfaff M: Integrin affinity
modulation. Trends Cell Biol. 8:359–364. 1998. View Article : Google Scholar
|
|
86
|
Hattori R, Hamilton KK, Fugate RD, McEver
RP and Sims PJ: Stimulated secretion of endothelial von Willebrand
factor is accompanied by rapid redistribution to the cell surface
of the intracellular granule membrane protein GMP-140. J Biol Chem.
264:7768–7771. 1989.PubMed/NCBI
|
|
87
|
Stenberg PE, McEver RP, Shuman MA, Jacques
YV and Bainton DF: A platelet alpha-granule membrane protein
(GMP-140) is expressed on the plasma membrane after activation. J
Cell Biol. 101:880–886. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Henn V, Slupsky JR, Gräfe M,
Anagnostopoulos I, Förster R, Müller-Berghaus G and Kroczek RA:
CD40 ligand on activated platelets triggers an inflammatory
reaction of endothelial cells. Nature. 391:591–594. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Daniel TO, Gibbs VC, Milfay DF, Garovoy MR
and Williams LT: Thrombin stimulates c-sis gene expression in
microvascular endothelial cells. J Biol Chem. 261:9579–9582.
1986.PubMed/NCBI
|
|
90
|
Papadimitriou E, Manolopoulos VG, Hayman
GT, Maragoudakis ME, Unsworth BR, Fenton JW II and Lelkes PI:
Thrombin modulates vectorial secretion of extracellular matrix
proteins in cultured endothelial cells. Am J Physiol.
272:C1112–C1122. 1997.
|
|
91
|
Wojtukiewicz MZ, Tang DG, Ben-Josef E,
Renaud C, Walz DA and Honn KV: Solid tumor cells express functional
'tethered ligand' thrombin receptor. Cancer Res. 55:698–704.
1995.
|
|
92
|
Camerer E: Protease signaling in tumor
progression. Thromb Res. 120:S75–S81. 2007. View Article : Google Scholar
|
|
93
|
Bohm SK, Kong W, Bromme D, Smeekens SP,
Anderson DC, Connolly A, Kahn M, Nelken NA, Coughlin SR, Payan DG
and Bunnett NW: Molecular cloning, expression and potential
functions of the human proteinase-activated receptor-2. Biochem J.
314:1009–1016. 1996.PubMed/NCBI
|
|
94
|
D'Andrea MR, Derian CK, Santulli RJ and
Andrade-Gordon P: Differential expression of protease-activated
receptors-1 and -2 in stromal fibroblasts of normal, benign, and
malignant human tissues. Am J Pathol. 158:2031–2041. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Darmoul D, Marie JC, Devaud H, Gratio V
and Laburthe M: Initiation of human colon cancer cell proliferation
by trypsin acting at protease-activated receptor-2. Br J Cancer.
85:772–779. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Nierodzik ML, Bain RM, Liu LX, Shivji M,
Takeshita K and Karpatkin S: Presence of the seven transmembrane
thrombin receptor on human tumour cells: effect of activation on
tumour adhesion to platelets and tumor tyrosine phosphorylation. Br
J Haematol. 92:452–457. 1996. View Article : Google Scholar
|
|
97
|
Henrikson KP, Salazar SL, Fenton JW II and
Pentecost BT: Role of thrombin receptor in breast cancer
invasiveness. Br J Cancer. 79:401–406. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Nierodzik ML, Chen K, Takeshita K, Li JJ,
Huang YQ, Feng XS, D'Andrea MR, Andrade-Gordon P and Karpatkin S:
Protease-activated receptor 1 (PAR-1) is required and rate-limiting
for thrombin-enhanced experimental pulmonary metastasis. Blood.
92:3694–3700. 1998.PubMed/NCBI
|
|
99
|
Gratio V, Walker F, Lehy T, Laburthe M and
Darmoul D: Aberrant expression of proteinase-activated receptor 4
promotes colon cancer cell proliferation through a persistent
signaling that involves Src and ErbB-2 kinase. Int J Cancer.
124:1517–1525. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Bergmann S, Junker K, Henklein P,
Hollenberg MD, Settmacher U and Kaufmann R: PAR-type thrombin
receptors in renal carcinoma cells: PAR1-mediated EGFR activation
promotes cell migration. Oncol Rep. 15:889–893. 2006.PubMed/NCBI
|
|
101
|
Jin E, Fujiwara M, Pan X, Ghazizadeh M,
Arai S, Ohaki Y, Kajiwara K, Takemura T and Kawanami O:
Protease-activated receptor (PAR)-1 and PAR-2 participate in the
cell growth of alveolar capillary endothelium in primary lung
adenocarcinomas. Cancer. 97:703–713. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Fischer EG, Ruf W and Mueller BM: Tissue
factor-initiated thrombin generation activates the signaling
thrombin receptor on malignant melanoma cells. Cancer Res.
55:1629–1632. 1995.
|
|
103
|
Kaufmann R, Henklein P, Henklein P and
Settmacher U: Green tea polyphenol epigallocatechin-3-gallate
inhibits thrombin-induced hepatocellular carcinoma cell invasion
and p42/p44-MAPKinase activation. Oncol Rep. 21:1261–1267. 2009.
View Article : Google Scholar
|
|
104
|
Faruqi TR, Weiss EJ, Shapiro MJ, Huang W
and Coughlin SR: Structure-function analysis of protease-activated
receptor 4 tethered ligand peptides. Determinants of specificity
and utility in assays of receptor function. J Biol Chem.
275:19728–19734. 2000. View Article : Google Scholar
|
|
105
|
Rickles FR, Levine M and Edwards RL:
Hemostatic alterations in cancer patients. Cancer Metastasis Rev.
11:237–248. 1992. View Article : Google Scholar
|
|
106
|
Walz DA and Fenton JW: The role of
thrombin in tumor cell metastasis. Invasion Metastasis. 14:303–308.
1994.PubMed/NCBI
|
|
107
|
Ruf W and Mueller BM: Tissue factor in
cancer angiogenesis and metastasis. Curr Opin Hematol. 3:379–84.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Palumbo JS and Degen JL: Hemostatic
factors in tumor biology. J Pediatr Hematol Oncol. 22:281–287.
2000. View Article : Google Scholar
|
|
109
|
Hejna M, Raderer M and Zielinski CC:
Inhibition of metastases by anticoagulants. J Natl Cancer Inst.
91:22–36. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Tellez C and Bar-Eli M: Role and
regulation of the thrombin receptor (PAR-1) in human melanoma.
Oncogene. 22:3130–3137. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Shi X, Gangadharan B, Brass LF, Ruf W and
Mueller BM: Protease-activated receptors (PAR1 and PAR2) contribute
to tumor cell motility and metastasis. Mol Cancer Res. 2:395–402.
2004.PubMed/NCBI
|
|
112
|
Even-Ram SC, Maoz M, Pokroy E, Reich R,
Katz BZ, Gutwein P, Altevogt P and Bar-Shavit R: Tumor cell
invasion is promoted by activation of protease activated receptor-1
in cooperation with the alpha vbeta 5 integrin. J Biol Chem.
276:10952–10962. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Turcotte S, Desrosiers RR, Brand G and
Béliveau R: von Hippel-Lindau tumor suppressor protein stimulation
by thrombin involves RhoA activation. Int J Cancer. 112:777–786.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Chay CH, Cooper CR, Gendernalik JD,
Dhanasekaran SM, Chinnaiyan AM, Rubin MA, Schmaier AH and Pienta
KJ: A functional thrombin receptor (PAR1) is expressed on
bone-derived prostate cancer cell lines. Urology. 60:760–765. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Bromberg ME, Bailly MA and Konigsberg WH:
Role of protease-activated receptor 1 in tumor metastasis promoted
by tissue factor. Thromb Haemost. 86:1210–1214. 2001.PubMed/NCBI
|
|
116
|
Fischer EG, Riewald M, Huang HY, Miyagi Y,
Kubota Y, Mueller BM and Ruf W: Tumor cell adhesion and migration
supported by interaction of a receptor-protease complex with its
inhibitor. J Clin Invest. 104:1213–1221. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Karpatkin S: Does hypercoagulability
awaken dormant tumor cells in the host? J Thromb Haemost.
2:2103–2106. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Yin YJ, Salah Z, Grisaru-Granovsky S,
Cohen I, Even-Ram SC, Maoz M, Uziely B, Peretz T and Bar-Shavit R:
Human protease-activated receptor 1 expression in malignant
epithelia: a role in invasiveness. Arterioscler Thromb Vasc Biol.
23:940–944. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
O'Brien PJ, Prevost N, Molino M, Hollinger
MK, Woolkalis MJ, Woulfe DS and Brass LF: Thrombin responses in
human endothelial cells. Contributions from receptors other than
PAR1 include the transactivation of PAR2 by thrombin-cleaved PAR1.
J Biol Chem. 275:13502–13509. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Zacharski LR and Ornstein DL: Heparin and
cancer. Thromb Haemost. 80:10–23. 1998.
|
|
121
|
Smorenburg SM, Hettiarachchi RJ, Vink R
and Büller HR: The effects of unfractionated heparin on survival in
patients with malignancy – a systematic review. Thromb Haemost.
82:1600–1604. 1999.
|
|
122
|
Zacharski LR, Ornstein DL and Mamourian
AC: Low-molecular-weight heparin and cancer. Semin Thromb Hemost.
26:69–77. 2000. View Article : Google Scholar
|
|
123
|
Teng LS, Jin KT, He KF, Wang HH, Cao J and
Yu DC: Advances in combination of anti-angiogenic agents targeting
VEGF-binding and conventional chemotherapy and radiation for cancer
treatment. J Chin Med Assoc. 73:281–288. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Teng LS, Jin KT, He KF, Zhang J, Wang HH
and Cao J: Clinical applications of VEGF-trap (aflibercept) in
cancer treatment. J Chin Med Assoc. 73:449–456. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Jin K, Shen Y, He K, Xu Z, Li G and Teng
L: Aflibercept (VEGF Trap): one more double-edged sword of
anti-VEGF therapy for cancer? Clin Transl Oncol. 12:526–532. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Edwards RL, Klaus M, Matthews E, McCullen
C, Bona RD and Rickles FR: Heparin abolishes the
chemotherapy-induced increase in plasma fibrinopeptide A levels. Am
J Med. 89:25–28. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Zangari M, Anaissie E, Barlogie B, Badros
A, Desikan R, Gopal AV, Morris C, Toor A, Siegel E, Fink L and
Tricot G: Increased risk of deep-vein thrombosis in patients with
multiple myeloma receiving thalidomide and chemotherapy. Blood.
98:1614–1615. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Varki NM and Varki A: Heparin inhibition
of selectin-mediated interactions during the hematogenous phase of
carcinoma metastasis: rationale for clinical studies in humans.
Semin Thromb Hemost. 28:53–66. 2002. View Article : Google Scholar
|
|
129
|
Collen A, Smorenburg SM, Peters E, Lupu F,
Koolwijk P, van Noorden C and van Hinsbergh VW: Unfractionated and
low molecular weight heparin affect fibrin structure and
angiogenesis in vitro. Cancer Res. 60:6196–6200. 2000.PubMed/NCBI
|
|
130
|
Mousa SA: Anticoagulants in thrombosis and
cancer: the missing link. Semin Thromb Hemost. 28:45–52. 2002.
View Article : Google Scholar
|
|
131
|
Norrby K and Ostergaard P:
Basic-fibroblast-growth-factor-mediated de novo angiogenesis is
more effectively suppressed by low-molecular-weight than by
high-molecular-weight heparin. Int J Microcirc Clin Exp. 16:8–15.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Hirsh J: Current anticoagulant therapy –
unmet clinical needs. Thromb Res. 109:S1–S8. 2003.
|
|
133
|
Weitz JI: A novel approach to thrombin
inhibition. Thromb Res. 109:S17–S22. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Pakala R, Liang CT and Benedict CR:
Inhibition of arterial thrombosis by a peptide ligand of the
thrombin receptor. Thromb Res. 100:89–96. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Covic L, Misra M, Badar J, Singh C and
Kuliopulos A: Pepducin-based intervention of thrombin-receptor
signaling and systemic platelet activation. Nat Med. 8:1161–1165.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Kasuda S, Sakurai Y, Shima M, Morimura Y,
Kudo R, Takeda T, Ishitani A, Yoshioka A and Hatake K: Inhibition
of PAR4 signaling mediates ethanol-induced attenuation of platelet
function in vitro. Alcohol Clin Exp Res. 30:1608–1614. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Derian CK, Maryanoff BE, Zhang HC and
Andrade-Gordon P: Therapeutic potential of protease-activated
receptor-1 antagonists. Expert Opin Investig Drugs. 12:209–221.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Wu CC and Teng CM: Comparison of the
effects of PAR1 anta- gonists, PAR4 antagonists, and their
combinations on thrombin-induced human platelet activation. Eur J
Pharmacol. 546:142–147. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Andrade-Gordon P, Maryanoff BE, Derian CK,
et al: Design, synthesis, and biological characterization of a
peptide-mimetic antagonist for a tethered-ligand receptor. Proc
Natl Acad Sci USA. 96:12257–12262. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Maryanoff BE, Zhang HC, Andrade-Gordon P
and Derian CK: Discovery of potent peptide-mimetic antagonists for
the human thrombin receptor, protease-activated receptor-1 (PAR-1).
Curr Med Chem Cardiovasc Hematol Agents. 1:13–36. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Zhang HC, Derian CK, Andrade-Gordon P, et
al: Discovery and optimization of a novel series of thrombin
receptor (par-1) antagonists: potent, selective peptide mimetics
based on indole and indazole templates. J Med Chem. 44:1021–1024.
2001. View Article : Google Scholar
|
|
142
|
Derian CK, Damiano BP, Addo MF, Darrow AL,
D'Andrea MR, Nedelman M, Zhang HC, Maryanoff BE and Andrade-Gordon
P: Blockade of the thrombin receptor protease-activated receptor-1
with a small-molecule antagonist prevents thrombus formation and
vascular occlusion in nonhuman primates. J Pharmacol Exp Ther.
304:855–861. 2003. View Article : Google Scholar
|
|
143
|
Chackalamannil S, Xia Y, Greenlee WJ,
Clasby M, Doller D, Tsai H, Asberom T, Czarniecki M, Ahn HS, Boykow
G, Foster C, Agans-Fantuzzi J, Bryant M, Lau J and Chintala M:
Discovery of potent orally active thrombin receptor (protease
activated receptor 1) antagonists as novel antithrombotic agents. J
Med Chem. 48:5884–5887. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Reséndiz JC, Kroll MH and Lassila R:
Protease-activated receptor-induced Akt activation – regulation and
possible function. J Thromb Haemost. 5:2484–2493. 2007.
|
|
145
|
Mao Y, Jin J, Daniel JL and Kunapuli SP:
Regulation of plasmin-induced protease-activated receptor 4
activation in platelets. Platelets. 20:191–198. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
Seiler SM and Bernatowicz MS:
Peptide-derived protease-activated receptor-1 (PAR-1) antagonists.
Curr Med Chem Cardiovasc Hematol Agents. 1:1–11. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Strande JL, Hsu A, Su J, Fu X, Gross GJ
and Baker JE: Inhibiting protease-activated receptor 4 limits
myocardial ischemia/reperfusion injury in rat hearts by unmasking
adenosine signaling. J Pharmacol Exp Ther. 324:1045–1054. 2008.
View Article : Google Scholar
|
|
148
|
Hollenberg MD and Saifeddine M:
Proteinase-activated receptor 4 (PAR4): activation and inhibition
of rat platelet aggregation by PAR4-derived peptides. Can J Physiol
Pharmacol. 79:439–442. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Ma L, Hollenberg MD and Wallace JL:
Thrombin-induced platelet endostatin release is blocked by a
proteinase activated receptor-4 (PAR4) antagonist. Br J Pharmacol.
134:701–704. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Kuliopulos A and Covic L: Blocking
receptors on the inside: pepducin-based intervention of PAR
signaling and thrombosis. Life Sci. 74:255–262. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Wu CC, Hwang TL, Liao CH, Kuo SC, Lee FY,
Lee CY and Teng CM: Selective inhibition of protease-activated
receptor 4-dependent platelet activation by YD-3. Thromb Haemost.
87:1026–1033. 2002.PubMed/NCBI
|
|
152
|
Sangawa T, Nogi T and Takagi J: A murine
monoclonal antibody that binds N-terminal extracellular segment of
human protease-activated receptor-4. Hybridoma. 27:331–335. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
153
|
O'Brien PJ, Molino M, Kahn M and Brass LF:
Protease activated receptors: theme and variations. Oncogene.
20:1570–1581. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Nantermet PG, Barrow JC, Lundell GF, et
al: Discovery of a nonpeptidic small molecule antagonist of the
human platelet thrombin receptor (PAR-1). Bioorg Med Chem Lett.
12:319–323. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Kato Y, Kita Y, Hirasawa-Taniyama Y,
Nishio M, Mihara K, Ito K, Yamanaka T, Seki J, Miyata S and Mutoh
S: Inhibition of arterial thrombosis by a protease-activated
receptor 1 antagonist, FR171113, in the guinea pig. Eur J
Pharmacol. 473:163–169. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Hollenberg MD, Saifeddine M, Sandhu S,
Houle S and Vergnolle N: Proteinase-activated receptor-4:
evaluation of tethered ligand-derived peptides as probes for
receptor function and as inflammatory agonists in vivo. Br J
Pharmacol. 143:443–454. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Covic L, Gresser AL, Talavera J, Swift S
and Kuliopulos A: Activation and inhibition of G protein-coupled
receptors by cell-penetrating membrane-tethered peptides. Proc Natl
Acad Sci USA. 99:643–648. 2002. View Article : Google Scholar : PubMed/NCBI
|
